Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Explore clinical trials studying Relapsed/Refractory Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

7 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Diffuse Large B-cell Lymphoma trial results

Recruiting

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT07409428

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China
  • Baoding NO.1 Central Hospital Baoding, China
  • Beijing GoBroad Hospital Beijing, China
  • BEIJING TONGREN HOSPITAL, Capital Medical University Beijing, China
View all 50 locations
View Trial Details
Completed

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04436107

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Beijing Friendship Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Sun Yat Sen University Cancer Center Guangzhou, Guangdong, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
View Trial Details
Completed

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

NCT03886831

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Anemia, +39 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UCSF Precision Cancer Medicine Building San Francisco, California, United States
  • Christiana Care Health Services, Christiana Hospital Newark, Delaware, United States
  • Florida Cancer Specialists Lake Mary, Florida, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers Chandler, Arizona, United States
  • Arizona Oncology Associates Tucson, Arizona, United States
  • The Oncology Institute (TOI) Clinical Research Cerritos, California, United States
  • Norton Cancer Institute, St. Matthews Louisville, Kentucky, United States
View all 38 locations
View Trial Details
Active, Not Recruiting

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT06601504

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Guangxi Medical University Cancer Hospital Nanning, Guangxi, China
  • Wuhan Union Hospital of China Wuhan, Hebei, China
View all 16 locations
View Trial Details

Related conditions